並列摘要
New therapeutic strategies for ovarian cancer treatment are still being explored. One potential target therapy of cancer is to dampen the epidermal growth factor receptor (EGFR) that regulates cell growth and differentiation in normal tissues and plays a role in cell proliferation, apoptosis inhibition, and angiogenesis in malignancy. EGFR is overexpressed in ovarian carcinomas ranging from 35% to 70%. Gefitinib (Iressa) is a low-molecular weight quinazoline derivative that specifically inhibits the activation of EGFR tyrosine kinase through competitive binding of the ATP-binding domain of the receptor. In this article, we reviewed the published articles in regard to the treatment of ovarian cancer by gefitinib.
被引用紀錄
劉杜鎮（2017）。在非小細胞肺癌中的生存素基因多態性和表皮生長因子受體突變之間的關聯〔博士論文，中山醫學大學〕。華藝線上圖書館。https://www.airitilibrary.com/Article/Detail?DocID=U0003-1201201719565900